Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin‐based chemotherapy resistance of colorectal cancer

The resistance against oxaliplatin (L‐OHP) based regimens remains a major obstacle for its efficient usage in treating metastatic colorectal cancer (mCRC). In this study, we performed weighted gene coexpression network analysis (WGCNA) to systematically screen the relevant hub genes for L‐OHP resistance using the raw microarray data of 30 consecutive mCRC samples from our earlier study (GSE69657). The results were further confirmed through datasets from Gene Expression Omnibus (GEO). From L‐OHP resistance module, nine genes in both the coexpression and protein–protein interaction networks were chosen as hub genes. Among these genes, Meis Homeobox 2 (MEIS2) had the highest correlation with L‐OHP resistance (r = −0.443) and was deregulated in L‐OHP resistant tissues compared with L‐OHP sensitive tissues in both our own dataset and GSE104645 testing dataset. The receiver operating characteristic curve validated that MEIS2 had a good ability in predicting L‐OHP response in both our own dataset (area under the curve [AUC] = 0.802) and GSE104645 dataset (AUC = 0.746). Then, the down expression of MEIS2 was observed in CRC tissue compared with normal tissue in 12 GEO‐sourced datasets and The Cancer Genome Atlas (TCGA) and was correlated with poor event‐free survival. Furthermore, analyzing methylation data from TCGA showed that MEIS2 had increased promoter hypermethylation. In addition, MEIS2 expression was significantly decreased in CRC stem cells compared with nonstem cells in two GEO datasets (GSE14773 and GSE24747). Further methylation analysis from GSE104271 demonstrated that CRC stem cells had higher MEIS2 promoter methylation levels in cg00366722 and cg00610348 sites. Gene set enrichment analysis showed that MEIS2 might be involved in the Wnt/β‐catenin pathway. In the overall view, MEIS2 had increased promoter hypermethylation and was downregulated in poor L‐OHP response mCRC tissues. MEIS2 might be involved in the Wnt/β‐catenin pathway to maintain CRC stemness, which leads to L‐OHP resistance. Meis Homeobox 2 (MEIS2) had increased promoter hypermethylation and was downregulated in poor L‐OHP response metastatic colorectal cancer (mCRC) tissues. MEIS2 expression was significantly decreased in CRC stem cells compared with nonstem cells. Further methylation analysis demonstrated that CRC stem cells had higher MEIS2 promoter methylation levels in cg00366722 and cg00610348 sites. MEIS2 might be involved in the Wnt/β‐catenin pathway to maintain CRC stemness, wh